Polycythemia Vera Guideline Updates 2023

Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.

In his final thoughts, Dr Gerds discusses emerging therapies for the treatment of PV.

Uncontrolled PV is highlighted by a key opinion leader.